Supportive Care and Antiemesis
Supportive care in oncology is the set of interventions that prevent and relieve the symptoms and complications of cancer and its treatment, rather than acting on the tumour itself. Antiemesis — the prevention and control of chemotherapy- and radiotherapy-induced nausea and vomiting — is one of its most developed components and a model for evidence-based symptom management.
Definition
Supportive care comprises measures aimed at preventing or relieving the symptoms and complications of cancer and its treatment, and antiemesis is the prevention and control of treatment-induced nausea and vomiting, guided by the emetogenic risk of the therapy.
Scope
This topic covers the principles of supportive cancer care and, in particular, the classification of emesis risk and the rationale for antiemetic strategies. It also touches on related supportive domains such as management of treatment-related symptoms. It is reference material describing concepts and evidence; it does not provide antiemetic regimens, dosing, or individualized recommendations.
Core questions
- What distinguishes supportive care from antitumour therapy?
- How is the emetogenic risk of anticancer therapy classified?
- What classes of antiemetic agents target which pathways of nausea and vomiting?
- How do acute, delayed, and anticipatory nausea and vomiting differ?
Key concepts
- Supportive (symptom-directed) care
- Emetogenic risk classification (high, moderate, low, minimal)
- Acute, delayed, and anticipatory nausea and vomiting
- 5-HT3 receptor antagonists
- NK1 receptor antagonists
- Corticosteroids as antiemetics
- Dopamine and other receptor pathways
- Guideline-based antiemetic strategy
Mechanisms
Treatment-induced nausea and vomiting is mediated by several neurotransmitter pathways, and antiemetic strategy is built around blocking them: serotonin (5-HT3) signaling is prominent in acute emesis, substance P acting at neurokinin-1 (NK1) receptors contributes to the delayed phase, and corticosteroids provide additional antiemetic benefit through less fully defined mechanisms. Because different anticancer agents and regimens carry different intrinsic emetogenic risk, supportive-care frameworks classify that risk and match prophylaxis to it. Nausea and vomiting are further categorized as acute, delayed, or anticipatory, each with distinct timing and contributing mechanisms.
Clinical relevance
Effective supportive care, and antiemesis in particular, reduces the symptom burden of cancer treatment and is a core measure of treatment quality. This entry explains the concepts and evidence base as educational reference; it is not a source of antiemetic protocols, drug selection, or dosing.
Epidemiology
Without preventive measures, nausea and vomiting are among the most distressing and frequent complications of cytotoxic therapy, particularly with highly emetogenic regimens; structured, guideline-based antiemetic prophylaxis has substantially reduced their incidence and severity.
History
Supportive oncology emerged as a distinct concern as cancer treatment intensified, and antiemesis advanced markedly with the introduction of 5-HT3 receptor antagonists and, later, NK1 receptor antagonists. Successive consensus guidelines from bodies such as MASCC, ESMO, and ASCO codified emetogenic-risk classification and evidence-based prophylaxis, making antiemesis a leading example of guideline-driven supportive care.
Key figures
- Paul J. Hesketh
- Fausto Roila
- Matti Aapro
Related topics
Seminal works
- roila-2016
- hesketh-2020
Frequently asked questions
- What is the difference between supportive care and palliative care?
- Supportive care broadly refers to preventing and relieving symptoms and complications of cancer and its treatment at any stage, including alongside curative therapy; it overlaps with palliative care, which emphasizes quality of life particularly in advanced disease.
- Why is antiemetic therapy chosen according to the type of chemotherapy?
- Different regimens carry different intrinsic risk of causing nausea and vomiting, so supportive-care frameworks classify that emetogenic risk and match the intensity of preventive treatment to it.